Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study.
(2016) Annals of Oncology — Vol. epub head of print, n° epub ahead of print, p. mdw561 (2016)
Files
document.pdf
Restricted Access - Adobe PDF
- 570.45 KB
Details
- Authors
- Abstract
- In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.
- Affiliations
Citations
Faivre, S., Niccoli, P., Castellano, D., Valle, J. W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J.-S., Ruszniewski, P., Seitz, J.-F., Patyna, S., Lu, D. R., et al. (2016). Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study. Annals of Oncology, epub head of print(epub ahead of print), mdw561. https://doi.org/10.1093/annonc/mdw561 (Original work published 2016)